Pulmonary tuberculosis remains an important public health problem despite extensive use of BCG vaccine to control its further spread. The incidence of tuberculosis in the United States is once again on the increase, particularly in homeless, alcoholic and AIDS patients. BCG vaccination is recommended for individuals at high risk (family members of tuberculosis patients, health care personnel, HIV infected individuals) despite concern regarding its effectiveness under some circumstances. Because of poor protection in a number of field trials, calls have been made for the development of new vaccines taking advantage of recent advances in molecular biology. We still know surprisingly little about the protective antigens of the tubercle bacillus or how they induce a protective cell-mediated immunity in the infected host. We also need to know which antigens (or epitopes) induce a strong memory immune T-cell response which will protect the vaccinated host against subsequent reinfection months or years later. Live mycobacteria secrete a number of protein antigens which are associated with the induction of T-cell immunity in appropriately vaccinated mice. The dynamics of this T-cell response (Tdth, Tcmi, Tmemory) will be followed in mice infected with BCG and restimulated with proteins present in culture filtrate concentrates. Monoclonal antibodies directed against selected, protective protein antigens will be used to screen various recombinant DNA vaccines bearing the putative protective genes of M. tuberculosis. Positive recombinants will be tested in vaccinated mice for protection against a fully virulent tuberculous challenge. The proposal is divided into 3 specific aims.
Aim 1. To compare the relative immunogenicity of M. tuberculosis with M.bovis (BCG) culture filtrate stress proteins.
Aim 2. To determine the ability of stress proteins to stimulate memory T-cell immunity.
Aim 3. To screen recombinant DNA vaccines for those protective BCG stress proteins. Hopefully this data will eventually lead to the development of more protective antituberculous vaccines for human use.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project (R01)
Project #
5R01AI027156-06
Application #
2063721
Study Section
Bacteriology and Mycology Subcommittee 2 (BM)
Project Start
1989-02-01
Project End
1995-08-31
Budget Start
1994-09-01
Budget End
1995-08-31
Support Year
6
Fiscal Year
1994
Total Cost
Indirect Cost
Name
Trudeau Institute, Inc.
Department
Type
DUNS #
City
Saranac Lake
State
NY
Country
United States
Zip Code
12983
Dunn, P L; North, R J (1996) Persistent infection with virulent but not avirulent Mycobacterium tuberculosis in the lungs of mice causes progressive pathology. J Med Microbiol 45:103-9
Dunn, P L; North, R J (1995) Virulence ranking of some Mycobacterium tuberculosis and Mycobacterium bovis strains according to their ability to multiply in the lungs, induce lung pathology, and cause mortality in mice. Infect Immun 63:3428-37
Collins, F M (1994) The immune response to mycobacterial infection: development of new vaccines. Vet Microbiol 40:95-110
Hubbard, R D; Flory, C M; Collins, F M (1992) Immunization of mice with mycobacterial culture filtrate proteins. Clin Exp Immunol 87:94-8
Hubbard, R D; Flory, C M; Collins, F M (1992) T-cell immune responses in Mycobacterium avium-infected mice. Infect Immun 60:150-3
Collins, F M (1992) Mycobacteria as cofactors in AIDS. Res Microbiol 143:369-72
Hubbard, R D; Collins, F M (1991) Immunomodulation of mouse macrophage killing of Mycobacterium avium in vitro. Infect Immun 59:570-4
Hubbard, R D; Flory, C M; Collins, F M (1991) Memory T cell-mediated resistance to Mycobacterium tuberculosis infection in innately susceptible and resistant mice. Infect Immun 59:2012-6
Collins, F M (1991) Antituberculous immunity: new solutions to an old problem. Rev Infect Dis 13:940-50
Collins, F M (1990) Dynamics of the phagocytic cell response within the lungs of parabiotic mice infected with mycobacteria with decreasing virulence for mice. Infect Immun 58:2303-8

Showing the most recent 10 out of 11 publications